Results 71 to 80 of about 1,034,808 (300)

Large-cell neuroendocrine carcinoma of the cervix

Rare Tumors, 2012
Large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is a rare and aggressive malignancy with poor prognosis even in its early stage, despite multimodality treatment strategy. Here, we report a case of a woman with clinical polypoid stage IB
Arkadiusz Z. Dudek, Alexander M. Truskinovsky, Ming Chi, Benyam Yoseph   +3 more
doaj   +1 more source

A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma [PDF]

, 2017
Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC) but neither this sensitivity nor specificity is absolute. This study is the first known comparison of CDX1 and A33 against CDX2 as immunomarkers for CRC.
Adamczyk, Lukasz A., Cullen, Jayne, Evans, Shanna, Oien, Karin A., Oniscu, Anca, Wong, Newton A.C.S.   +5 more
core   +1 more source

Update on large cell neuroendocrine carcinoma [PDF]

Translational Lung Cancer Research, 2017
High-grade neuroendocrine carcinomas of the lung are classified into two categories: large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). While typical cases of LCNEC are morphologically distinct from SCLC, the differentiation between LCNEC and SCLC can be challenging in some cases.
Kenzo, Hiroshima, Mari, Mino-Kenudson
openaire   +2 more sources

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma

Frontiers in Oncology
Combined large cell neuroendocrine carcinoma (CLCNEC) is a rare neuroendocrine carcinoma, accounting for approximately 10% of large cell neuroendocrine carcinoma (LCNEC).
Kai Kang, Binfeng Li, Sheng Wang, Jianjian Wang, Xinjun Liang   +4 more
doaj   +1 more source

Large cell neuroendocrine carcinoma of the kidney with cardiac metastasis: a case report

Journal of Medical Case Reports, 2017
Background Primary large cell neuroendocrine carcinoma of the kidney is a rare and generally very aggressive disease. We present a case of a patient with primary large cell neuroendocrine carcinoma of the kidney with cardiac metastasis. Case presentation
Moeka Shimbori, Kimito Osaka, Takashi Kawahara, Ryo Kasahara, Sayuki Kawabata, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Shoji Yamanaka, Masahiro Yao   +9 more
doaj   +1 more source

Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC:is there evidence to support a prognostic or diagnostic role? [PDF]

, 2014
BACKGROUND: Tobacco, alcohol and HPV infection are associated with increased risk of HNSCC. However, little is known about the underlying signaling events influencing risk.
Cochrane, Lynda, Ellis, Ian R., Islam, Mohammad R., Jones, Sarah J., Macluskey, Michaelina   +4 more
core   +3 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Lung cancer at a university hospital in Saudi Arabia: A four-year prospective study of clinical, pathological, radiological, bronchoscopic, and biochemical parameters

Annals of Thoracic Medicine, 2010
Objectives and Background: Lung cancer accounts for 4% of all newly diagnosed cancers in Saudi Arabia. The pattern of presentation is unknown. The objectives of this study were to assess the clinical, radiological, pathological, biochemical and ...
Alamoudi Omer
doaj  

Metallopanstimulin as a marker for head and neck cancer [PDF]

, 2004
BACKGROUND: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC).
A Agrawal, A Dietz, BC Stack Jr, CS Hollenbeak, DJ Santa Cruz, DR Ganger, DR Ganger, E Tartour, H Kasai, H Naora, H Quon, IG Wool, IG Wool, JA Fernandez-Pol, JA Fernandez-Pol, JA Fernandez-Pol, JA Fernandez-Pol, JA Fernandez-Pol, JT Wadsworth, JT Wadsworth, M Schmidt, PA Rockledge, RR Million, TN Teknos, VJ Lowe, WJ Lee, Y Atsuta, YL Chan, YL Chan   +28 more
core   +4 more sources